Skip to content

Return on assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
8.1%+2.5pp
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
-2%-6.7pp
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-36%+8.4pp
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-33.7%-10.0pp
Biohaven logo
BiohavenBHVN
-140%-33.0pp
Septerna, Inc. logo
Septerna, Inc.SEPN
-7.2%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.86B+309%
Enterprise value$1.79B+352%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Calculated from Rapport Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s return on assets?
Rapport Therapeutics, Inc. (RAPP) reported return on assets of -26.8% in Q1 2026.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.